

# 급성기 정신병 환자에서 Olanzapine의 임상적 사용

김 찬 형<sup>1,2</sup> · 김 영 기<sup>1</sup>

연세대학교 의과대학 정신과학교실,<sup>1</sup> 의학행동과학연구소<sup>2</sup>

## ABSTRACT

### Olanzapine for the Acutely Agitated Psychotic Patients

Chan-Hyung Kim, MD, PhD<sup>1,2</sup> and Young Kee Kim, MD<sup>1</sup>

<sup>1</sup>Department of Psychiatry and <sup>2</sup>Institute of Behavioral Science in Medicine,  
Yonsei University College of Medicine, Seoul, Korea

Agitation is a common and urgent condition involving motor hyperactivity and symptoms such as irritability, combativeness, or impaired judgement. Rapid assessment and effective treatment are necessary to manage agitation and, potentially, to shorten the time to recovery. Rapid treatment with intramuscular (IM) typical antipsychotics and/or benzodiazepines may be essential to prevent injury to the patients or others. However, IM typical antipsychotics are associated with acute extrapyramidal side effects, and IM benzodiazepines may cause excessive sedation leading to respiratory depression, ataxia, and confusion. Recently, an IM formulation of olanzapine may present several treatment advantages when rapid treatment of acute agitation is essential in patients with schizophrenia, bipolar disorder, and others. In addition, rapid initial dosing with olanzapine may be a useful approach to manage acute agitation in some patients with schizophrenia. (Korean J Psychopharmacol 2005;16 (Supplement 1):71-76)

**KEY WORDS** : Acute psychosis · Olanzapine.

## 서 론

(agitation)

haloperidol fluphenazine

lorazepam

benzodiazepine 가

zepine

, parkinsonism

가 , benzodia-

benzodiazepine

교신저자 : , 135 - 720

146 - 92

: (02) 3497 - 3340 · : (02) 3462 - 4304

E - mail : spr88@yumc.yonsei.ac.kr

, 가

## Olanzapine

가<sup>1)</sup> ( , , , )  
 , 가  
 가 .  
 ziprasidone olanzapine ,  
 가  
 olanzapine (oral  
 loading)  
 ,  
 pine , olanza-  
 ,  
 , Benzodiazepine  
 ,  
 ,<sup>5)</sup>

## 과거 약물치료

1

## 급성기 정신병적 증상

, , ,  
 , benzodiazepine  
 ( 30~60  
 ).<sup>6,7)</sup>  
 ,<sup>8)</sup>  
 ,  
 ,  
 Haloperidol fluphenazine 가  
 가<sup>2)</sup>  
 가<sup>3)</sup>  
 ,  
 가 ,  
 가  
 가<sup>9)</sup>  
 ,<sup>2)</sup>  
 ,  
 가

haloperidol 100 mg  
<sup>10)</sup>  
 10 mg haloperidol  
<sup>11)</sup>  
 가  
<sup>12,13)</sup>  
<sup>10,12-15)</sup> 1

## 2. Quetiapine

Chengappa Goldstein <sup>19)</sup> quetiapine, quetiapine, haloperidol  
 tiapine haloperidol

McManus <sup>20)</sup> 65  
 151 12  
 , BPRS CGI -  
 가 AIMS

## 비정형 항정신병 약물(Olanzapine 제외)

clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole  
 olanzapine  
 olanzapine, 가  
 aripiprazole

risperidone olanzapine quetiapine  
 가 가 Raja Azzoni  
<sup>21)</sup> risperidone olanzapine  
 quetiapine 가

1. Risperidone  
 Currier <sup>16)</sup> 2 mg risperidone 2 mg lorazepam 5 mg haloperidol  
 2 mg lorazepam  
 , risperidone  
 haloperidol  
 Pajonk <sup>17)</sup> 1,117  
 6 risperidone PANSS  
 CGI, BPRS 가  
 가  
 . Emsely McCreadie <sup>18)</sup> 6 가 halo-  
 peridol risperidone haloperidol  
 PANSS  
 (63% 56%)

## 3. Ziprasidone

Ziprasidone  
 ziprasidone 가  
 . Brook <sup>22)</sup> ziprasidone  
 haloperidol  
 가 . Brook Lucey  
<sup>23)</sup> ziprasidone BPRS  
 BPRS , CGI -  
 haloperidol

## Olanzapine

### 1. 근주형 olanzapine

olanzapine  
 olanzapine

## Olanzapine

- olanzapine 24 PANSS - EC - 7.1[4.8] vs - 6.7[4.3], ).
- 1) Wright 등의 연구<sup>24)</sup>
- olanzapine 10 mg, haloperidol 7.5 mg, 1~3 , PANSS - EC 2 가 가 (agitated behavior scale, ABS ; agitation calmness evaluation scale, ACES) . PANSS - EC olanzapine haloperidol 2~24 (6.5% vs 18.5%, ; p=0.015).
- olanzapine haloperidol 15 ( - 4.1 - 2.4, p<0.001), 30 ( - 6.3 - 4.3, p<0.001), 45 ( - 7.6 - 6.2, p=0.01) . olanzapine haloperidol 1~3 olanzapine 2 PANSS - EC 가 가 24 가 , olanzapine 7% 가 , ha- loperidol (p=0.001). QTc interval
- 2) Wright와 Meehan 등의 연구<sup>25)</sup>
- 24 10 mg olanzapine 7.5 mg halo- peridol 1~3 , 4 ( 5~20 mg/day). , PANSS - EC 가 . EPS 가 가 . 311 ( 204 , 107 ; 38.2 )가 (olanzapine 131 , haloperidol 126 , 54 ), olanzapine 93.1%(122/131) haloperidol 92.1% (116/126)가 ; Olanzapine 85.5%(112/131) haloperidol 84.1%(106/126)가
- 3) Breier 등의 연구<sup>26)</sup>
- 24 olanzapine (2.5, 5.0, 7.5, 10.0 mg) haloperidol(7.5 mg), 1~3 . olanzapine - 가 2 PANSS - EC 가 . 24 가 , olanzapine - (F=14.4, p<.001). Olanzapine 2 PANSS - EC (2.5 mg= - 5.5 ; 5.0 mg= - 8.1 ; 7.5 mg= - 8.7 ; 10.0 mg= - 9.4)가 ( - 2.9 ; olanzapine 2.5 mg p=.01 ; olanzapine p<.001) , halope- ridol( - 7.5) . 5.0, 7.5, 10.0 mg olanzapine 30 , 가 , QTc interval haloperidol 2.5(p=.03), 5.0(p=.03), 7.5 mg(p=.01) olanzapine(0%) (0%)(p=.01) parkinsonism .
- 4) Lindborg 등의 연구<sup>27)</sup>
- QTc

QTc interval : 4 10 mg olanzapine  
 - [ 2 , 1 (15 mg 11 , 20 mg 43 , 25 mg 2 ,  
 (n=565)] ; haloperidol - [ 2 30 mg 1 ). CGI care score, tran-  
 (n=204)] ; - [ 1 quilization score, , 4  
 (n=204)]. 1~3 olanzapine (2.5~  
 10 mg), haloperidol (7.5 mg),  
 . olanzapine 2 24  
 haloperidol database QTc  
 interval 3 ms . olanzapine  
 가 , QTc  
 interval olanzapine  
 가 . olanzapine ( ha-  
 looperidol - database 3% , -  
 database 12% ) (endpoint  
 99%tile 500 ms )  
 (60 ms 가) QTc interval  
 .  
 olanzapine ,

## 2. Olanzapine의 초기 급격 증량(oral loading)

olanzapine  
 halope-  
 ridol  
 . Kinon <sup>1)</sup>  
 olanzapine haloperidol  
 , 3 20 mg  
 . 24  
 1 , PANSS agita-  
 tion subscale 가 ,  
 1 PANSS agitation score  
 ( - 5.79 ± 6.30 for  
 olanzapine, - 4.89 ± 6.05 for haloperidol, p<.001).  
 lorazepam  
 가 , halo-

peridol (67.3% vs. 85.4%,  
 p=.038).

Karagianis <sup>28)</sup> 57  
 4 10 mg olanzapine  
 (15 mg 11 , 20 mg 43 , 25 mg 2 ,  
 30 mg 1 ). CGI care score, tran-  
 quilization score, , 4  
 olanzapine  
 (20 mg 20 mg )  
 . 4 20 mg  
 olanzapine  
 (14.74 mg 16.88 mg),  
 ( )  
 ( ) ). Baker

<sup>5)</sup> 148  
 가 ;  
 (rapid initial dose escalation, RIDE) 1  
 2 olanzapine 40 mg ,  
 3 4 30 mg , 5~  
 20 mg . (usual clinical  
 practice, UCP) 1 2 10 mg olan-  
 zapine 4 mg lorazepam , 3 4  
 10 mg olanzapine 2 mg lorazepam  
 , olanzapine 5~20 mg  
 . 24 PANSS - EC가  
 , (overt agitation severity scale,  
 OASS ; CGI - Agitation)  
 가 .  
 ( 7.01 ±  
 0.5 : 5.51 ± 0.46, p<0.0001), RIDE  
 UCP (p=0.006).

(p=0.004).

가

## 결론

## Olanzapine

가  
pam 가  
가  
olanzapine  
olanzapine haloperidol  
olanzapine oral loading  
중심 단어 : Olanzapin.

## 참고 문헌

- 1) Kinon BJ, Ahl J, Rotteli MD, McMullen E. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. *Am J Emerg Med* 2004; 22:181-186.
- 2) Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The expert consensus guideline series. Treatment of behavioral emergencies. *J Postgrad Med* 2001; May:88-90.
- 3) Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. *J Clin Psychiatry* 2000; 61 (suppl 14):11-22.
- 4) Feifel D. Rationale and guidelines for the inpatient treatment of acute psychosis. *J Clin Psychiatry* 2000; 61 (suppl 14):27-32.
- 5) Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. *J Clin Psychopharmacol* 2003; 23:342-348.
- 6) Mason AS, Granacher RP. Basic principles of rapid neuroleptization. *Dis Nerv Syst* 1976; 37:547-551.
- 7) Ayd FJ. Guidelines for using short-acting intramuscular neuroleptics for rapid neuroleptization. *Int Drug Ther Newslett*. 1977; Feb-March:5-12.
- 8) Marder SR. Pharmacological treatment strategies in acute schizophrenia. *Int Clin Psychopharmacol* 1996; 11 (suppl 2):29-34.
- 9) Ayd FJ Jr. Guidelines for using intramuscular haloperidol for rapid neuroleptization. In: Ayd FJ Jr. ed. *Haloperidol Update: 1958-1980*. Baltimore, Md: Ayd medical Communications; 1980.
- 10) Donlon PT, Hopkin J, Rupin JP. Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol. *Am J Psychiatry* 1979; 136:273-278.
- 11) Neborsky R, Janowsky D, Munson E, Depry D. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol: behavioral considerations. *Arch Gen Psychiatry*. 1981; 38:195-199.
- 12) Van Putten T, Marder SR, Minitz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. *Arch Gen Psychiatry* 1990; 47:726-729.
- 13) Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, Stephanos MJ, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. *Arch Gen Psychiatry* 1990; 47:726-729.
- 14) Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, et al. Haloperidol blood levels and clinical effects. *Arch Gen Psychiatry* 1992; 49:354-361.
- 15) Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M. Dosage of haloperidol for schizophrenia. *Arch Gen Psychiatry* 1991; 48:166-170.
- 16) Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. *J Clin Psychiatry* 2004; 65:386-394.
- 17) Pajonk FG, Schreiner A, Peters S, Rettig K, Degner D, Ruther E. Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients: an interim analysis. *Fortschr Neurol Psychiatr* 2003; 71:249-254.
- 18) Emsley RA, McCreadie JF. Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multi-center study [poster]. Presented at Campaign on Schizophrenia Conference "critical issues in treatment". Florence. March; 1995.
- 19) Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J. Post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. *Clin Ther* 2003; 25:530-541.
- 20) McManus DQ, Arvanitis LA, Kowalczyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. *Seroquel Trial 48 Study Group. J Clin Psychiatry* 1999; 60:292-298.
- 21) Michele Raja, Antonella Azzoni. Comparison of three antipsychotics in the emergency psychiatric setting. *Hum Psychopharmacol Clin Exp* 2003; 18:447-452.
- 22) Brook S. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. *J Clin Psychiatry* 2003; 64 (suppl 19):13-18.
- 23) Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. *J Clin Psychiatry* 2000; 61:933-941.
- 24) Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. *Am J Psychiatry* 2001; 158:1149-1151.
- 25) Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. *Clin Ther* 2003; 25:1420-1428.
- 26) Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. *Arch Gen Psychiatry* 2002; 59:441-448.
- 27) Lindborg SR, Beasley CM, Alaka K, Taylor CC. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. *Psychiatry Res* 2003; 119:113-123.
- 28) Karagianis JL, Dawe IC, Thakur A, Begin S, Raskin J, Roychowdhury SM. Rapid tranquilization with olanzapine in acute psychosis: a case series. *J Clin Psychiatry* 2001; 62 (suppl 2):12-16.